StockNews.com Begins Coverage on Evogene (NASDAQ:EVGN)

Stock analysts at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a research report issued on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.

Evogene Stock Performance

EVGN opened at $1.85 on Friday. Evogene has a one year low of $1.20 and a one year high of $10.40. The company has a market cap of $9.93 million, a P/E ratio of -0.41 and a beta of 1.30. The business’s 50-day simple moving average is $1.69 and its 200-day simple moving average is $3.21.

Hedge Funds Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC acquired a new position in shares of Evogene Ltd. (NASDAQ:EVGN) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Hedge funds and other institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.